← Leaderboards
Troy Lister
Spero Therapeutics, Inc.
$3,584,409
Attributed
$3,584,409
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2021–23$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
Funding mix
By agency
NIH$3,584,409 · 1
By mechanism
N01$3,584,409 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Lynn Briscoe · Leidos Biomedical Research, Inc.$110,540,429
- Ted Ross · University Of Georgia$68,763,143
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$57,713,529
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Research focus
Pre-ClinicalProduct DevelopmentResearch And DevelopmentResearch Clinical TestingSafety AssessmentTherapeutic CandidateAntibiotic ResistanceChemistryEfficacy EvaluationGram-Negative BacteriaAdvanced DevelopmentNovel TherapeuticsAnti-Bacterial AgentsPathway InteractionsPhase I TrialManufactureBacterial Drug ResistanceBacterial ResistanceBiodefenseAcinetobacterPathogen